
Sunshine House mobile drug site in limbo after RV totalled
Sunshine House was given an ambulance by the Salvation Army, but federal regulations require it to be approved.
'We're following all the guidelines and rules around this type of service, but because we're the only service in the province that does this, there is a sense of urgency to find a solution,' executive director Levi Foy said Friday.
MIKE DEAL / FREE PRESS FILES
Sunshine House's RV was totalled in a hit-and-run on July 2.
The Mobile Overdose Prevention Site would help, on average, 500 people per day by giving them harm-reduction supplies, supervising their drug consumption and testing their drugs on a mass spectrometer.
The RV needs a federal exemption from drug laws to be operable. Supervised consumption sites require an exemption under section 56.1 of the federal Controlled Drugs and Substances Act, Health Canada says.
Foy is concerned that approval could take another month; he's heard anecdotes from staff and community members that overdoses have gone up since the RV left the road.
Foy said he has been told there have been negative reactions to substances being sold as meth, but without the mass spectrometer, there's no way of knowing what is causing the effects.
'We don't really have a back door option and we don't really have any other ability to deliver services,' Foy said.
In July, supervised consumption site advocate Safer Sites issued a drug alert warning the public a substance tested at another location came back positive for para-fluorofentanyl, a synthetic opioid, and was connected to five overdoses.
Another notice stated a substance sold as the street drug 'down' was suspected to be related to 19 emergency calls requiring the use of naloxone over a 24-hour period on July 29.
A review of city data shows the Winnipeg Fire Paramedic Service responded to 249 calls where naloxone was administered 438 times, down from June's 330 calls and 612 administrations.
In its most recent annual report, the mobile overdose van recorded more than 26,000 visits from Oct. 28, 2022 to Oct. 31, 2023. There were 7,086 visits to consume drugs, which resulted in 20 overdose incidents, four trips to the hospital and no deaths.
Arlene Last-Kolb, co-founder of Overdose Awareness Manitoba and a member of Moms Stop the Harm, worries about what could happen to the downtown core if services are interrupted long-term.
'We know our supply is so toxic that having a safe consumption site… to me, is essential,' she said.
Preliminary data from the province shows there were 570 suspected substance-related deaths in 2024.
In the first two months of 2025, 81 people died owing to suspected substance-related deaths.
Foy said that without the supervised consumption service, drug users can only do so nearby and staff can check on them or offer them space in the ambulance afterward.
Tuesdays
A weekly look at politics close to home and around the world.
The gap in service underscores the urgent need for the supervised consumption site promised by the NDP government, Last-Kolb said.
'If I had a child, I'd be very worried right now,' she said.
In early July, Addictions Minister Bernadette Smith said the province is 'moving toward' having a site operating in Winnipeg by year's end.
Health Canada lists the Winnipeg application as being in the 'review' stage and 'awaiting key information before decision can be taken.'
nicole.buffie@freepress.mb.ca
Nicole BuffieMultimedia producer
Nicole Buffie is a reporter for the Free Press city desk. Born and bred in Winnipeg, Nicole graduated from Red River College's Creative Communications program in 2020 and worked as a reporter throughout Manitoba before joining the Free Press newsroom as a multimedia producer in 2023. Read more about Nicole.
Every piece of reporting Nicole produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
12 hours ago
- CTV News
29 cases of parasitic infection in Saskatoon Farm outbreak: AHS
Alberta Health Services is continuing to investigate the source of a gastrointestinal outbreak at the Saskatoon Farm's restaurant in July. (File) Alberta Health Services says there are now nearly 30 cases of a serious parasitic infection in connection with an outbreak of gastrointestinal illness at a restaurant at a southern Alberta business last month. AHS says as of Aug. 1, there are 49 probable cases of E. coli among customers who ate at the Saskatoon Farm, east of Okotoks, between July 1 and 18. The agency says among those patients, there have been 29 cases of Entamoeba histolytica (E. histolytica) infections. One person remains in hospital in connection with the outbreak while two other patients have been released. According to Health Canada, E. histolytica is a worldwide pathogen and the second leading cause of parasitic death. 'It infects an estimated 500 million people per year, causes liver abscess and colitis in 50 million, and results in death of an estimated 40,000-100,000 individuals annually,' the government's website says. Infections are more common in tropical and subtropical areas, such as Mexico, South and West Africa, western South America and South Asia, Health Canada says. Saskatoon Farm restaurant remains closed According to the latest inspection report of the restaurant at Saskatoon Farm, which was conducted on July 29, AHS said two violations were found. Those included the presence of pests in the restaurant and 'a practice or condition at this food establishment is creating a nuisance.' Officials said a live mouse was seen in the Saskatoon Farm bakery at the time of the inspection. No further information was provided by AHS about the 'nuisance' present at the business.


The Market Online
14 hours ago
- The Market Online
RDT submits QuickStrip nicotine product for Health Canada approval
Rapid Dose Therapeutics (CSE:DOSE) submitted a product application to Health Canada for its QuickStrip nicotine products in 1 mg to 4 mg formats, a big step toward commercialization QuickStrip is a fast-dissolving oral thin film designed to deliver nicotine, currently undergoing clinical trials comparing its efficacy to traditional cigarettes RDT's innovation aims to align with Canada's tobacco reduction goals and global harm reduction efforts, with plans for national launch and international expansion upon approval Rapid Dose Therapeutics stock (CSE:DOSE) last traded at $0.17 Rapid Dose Therapeutics (CSE:DOSE) officially submitted a product application to Health Canada for its QuickStrip nicotine products in 1 mg, 2 mg, 3 mg, and 4 mg formats. This regulatory milestone marks a pivotal step toward the commercialization of RDT's proprietary oral nicotine delivery system, developed as a safer alternative to smoking. This content has been prepared as part of a partnership with Rapid Dose Therapeutics Corp. and is intended for informational purposes only. QuickStrip is a fast-dissolving oral thin film designed to deliver active ingredients directly through the oral mucosa. The NicStrip product line utilizes this platform to offer nicotine in a controlled, smoke-free format, aimed at helping adult smokers reduce or quit tobacco use. The product is currently undergoing a pharmacokinetic clinical trial comparing QuickStrip Nicotine to traditional combustible cigarettes to evaluate absorption and efficacy. The study, conducted under Good Clinical Practice guidelines, is expected to provide critical data on nicotine bioavailability and support product claims for regulatory approval. 'Our QuickStrip delivery system is designed to mimic the nicotine absorption curve of a cigarette without the harmful by products of combustion,' Jason Lewis, RDT'S senior vice president explained in news release. 'It provides rapid onset, consistent dosing, and eliminates second-hand smoke-critical attributes for any successful smoking cessation or harm reduction strategy.' Over the past 30 months, RDT has collaborated with a leading global cigarette manufacturer to refine the QuickStrip nicotine product in preparation for launch. This strategic partnership has enabled extensive research and development focused on product optimization. In parallel, RDT and its production partner Aavishkar have filed two international patent applications under the Patent Cooperation Treaty, covering innovations in nicotine delivery, film formulation, and controlled-release technology. The inclusion of multiple dose strengths allows users to personalize their nicotine intake and taper use over time, supporting individualized cessation plans. Upon regulatory approval, RDT plans to launch the product across Canada and expand distribution through commercial partnerships, including potential licensing in international markets. This initiative aligns with the Government of Canada's Tobacco Strategy, which aims to reduce tobacco use to less than 5 per cent by 2035, and supports the World Health Organization's goal of reducing adult smoking prevalence by 30 per cent by 2030 under the WHO Framework Convention on Tobacco Control. Rapid Dose Therapeutics previously submitted a nicotine product application to Health Canada in 2019, but the process was delayed due to the COVID-19 pandemic. The Canadian nicotine pouches market was valued at US$112.2 million in 2024, with projected annual growth of 4.7 per cent through 2030, driven by increased demand for discreet, smoke-free alternatives and a growing public health focus on harm reduction. About Rapid Dose Therapeutics Rapid Dose Therapeutics Corp. is a Canadian life sciences company committed to developing and commercializing innovative drug delivery technologies. Its flagship QuickStrip platform offers rapid, convenient, and effective delivery of active ingredients, supporting a wide range of therapeutic applications. Rapid Dose Therapeutics stock (CSE:DOSE) last traded at $0.17 and has lost 20.45 per cent since the year began. Join the discussion: Find out what the Bullboards are saying about Rapid Dose Therapeutics and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .


CBC
2 days ago
- CBC
Tick-borne diseases on rise due to warmer temperatures, experts say
With warmer weather, Health Canada is warning about the growing risk of tick-borne illnesses like Lyme disease now spreading to new regions. Dr. Christopher Labos weighs in and also talks about staying safe amid widespread air quality alerts due to wildfire smoke.